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Abstract
Background: The Philadelphia (Ph) chromosome, or derivative chromosome 22 [der(22)], is a product of the
reciprocal translocation t(9;22). It is the hallmark of chronic myelogenous leukemia (CML). It results in juxtaposition
of the 5’ part of the BCR gene on chromosome 22 to the 3’ part of the ABL1 gene on chromosome 9. During CML
progression 60–80 % of the cases acquire additional genetic changes. Blast crisis (BC) is characterized by the rapid
expansion of a population of differentiation arrested blast cells (myeloid or lymphoid cells population), often
presenting with secondary chromosomal abnormalities. Here we report an unusual CML-BC case with acquired
secondary chromosomal aberrations observed after the patient had to interrupt a successful Imatinib treatment for
overall 16 months.
Case presentation: A complete cytogenetic and molecular cytogenetic analysis were performed and application of
molecular genetic methods such as reverse transcription polymerase chain reaction (RT-PCR) finally characterized a
complex karyotype including an inv dup(22)(q11.23), tetrasomy 8 and trisomy 19.
Conclusions: Here we report the first case of a BC after successfully initiated and suddenly interrupted Imatinib
treatment. Changes present after such an instant indicate for a rapid progression after Imatinib is no longer
suppressing the disease.
Keywords: Chronic myeloid leukemia, Philadelphia chromosome, inv dup(22)(q11.23), Tetrasomoy 8, Clonal
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Background
Chronic myeloid leukemia (CML) is a myeloprolifera-
tive disorder associated with the presence of Philadel-
phia (Ph) chromosome or also is called a derivative
chromosome 22 [der(22)]. The latter is found as sole
aberration in more than 90 % of the early chronic
phase (CP) CML cases and it is due to a reciprocal
translocation t(9;22)(q34.1;q11.2). This rearrangement
involves the breakpoint cluster region (BCR) gene
22q11.2 and the c-Abelson proto-oncogene (ABL1)
gene in 9q34, generating a chimeric BCR-ABL gene
that encodes a constitutively activated protein tyrosine
kinase. The kinase activity of BCR-ABL is essential
for the pathogenesis of CML [1].
Additional genetic changes occur in less than 10 % of
CML cases at diagnosis; other genetic changes are de-
tectable in 60-80 % of the cases in advanced disease [ac-
celerated phase (AP) and blast crisis (BC)] [1]. The
correct identification of such abnormalities is important
for diagnosis of the diseases determined by the WHO
Tumor Classification [2] and for treatment purposes.
The first therapeutic choice, tyrosine kinase inhibitors,
has shown great therapeutic efficacy [3].
Imatinib mesylate (IM =Glivec, formerly called STI571)
is a chemically designed drug able to block BCR/ABL1
tyrosine kinase activity and is successfully used as a first-
* Correspondence: walashkar@aec.org.sy
1Department of Molecular Biology and Biotechnology, Atomic Energy
Commission, Human Genetics Division, P.O. Box 6091, Damascus, Syria
Full list of author information is available at the end of the article
© 2015 Wafa et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wafa et al. Molecular Cytogenetics  (2015) 8:98 
DOI 10.1186/s13039-015-0204-x
line therapy for all CML patients [4]. It has significantly
improved the prognosis especially for newly diagnosed
CML-CP patients, in which the complete hematologic re-
sponse rate was more than 90 %, and the complete cyto-
genetic response rate 70-80 %. However, IM resistance has
emerged as an important clinical challenge. Multiple
factors may contribute to IM resistance including muta-
tions of BCR-ABL1 kinase domain, BCR-ABL1 amplifica-
tion or enhanced expression rates, clonal evolution, and
decrease in imatinib bioavailability or cell exposure [5].
Amplification can be determined by fluorescence in
situ hybridization (FISH) or comparative genome
hybridization (CGH), while other aforementioned
developments are difficult to monitor.
Here we presented a new CML-BC case with complex
karyotypic changes including an inv dup(22)(q11.23) in a
patient with an interrupted IM treatment; to the best of
our knowledge the outcome of such a case was not pre-
viously reported.
Case presentation
In June 2011 a 62-year-old Syrian male was diagnosed
as suffering from CML. Physical examination revealed
splenomegaly, which was the indicative symptom.
Routine peripheral blood test showed elevated white
blood cells (WBC) of 170.1 × 109/l (43.2 % neutro-
phils, 7.9 % lymphocytes, 11.2 % monocytes, 28.1 ba-
sophiles, and 9.6 % eosinophiles), red blood cell
(RBC) count was 3.05 × 106/mm3, hemoglobin level
was 6.1 g/dl and the platelet count was 1,039 × 109/l.
The patient was diagnosed as CML-AP according to
WHO recommendations. The patient did not receive
any previous treatment.
The patient was referred for a second time in July
2012 and was successfully treated with IM (400 mg/day)
for 13 months. The more recent routine peripheral
blood test was: WBC 5.3 × 109/l (52.1 % neutrophils,
34.8 % lymphocytes, 10.5 % monocytes, 0.5 basophiles,
and 2.1 % eosinophiles), RBC count was 2.98 × 106/mm3.
The platelet count was 203 × 109/l and the hemoglobin
level was 10.9 g/dl. Serum lactate dehydrogenase value
(LDH) was 512 U/l (normal level <460 U/l).
The patient was referred for a third time in May 2014
after he stopped IM treatment for 16 months due to pol-
itical situation in his home country. WBC was then
1,334.0 × 109/l (92 % of cells were blasts), red blood cell
(RBC) count was 1.91 × 106/mm3, hemoglobin level was
6.1 g/dl and the platelet count was 56 × 109/l. The pa-
tient was diagnosed as CML-BC according to WHO rec-
ommendations, in a high Sokal risk of 2,594 (0.8–1.2),
high Hasford (Euro) risk of 6039 (>1,480), and Etous
probability of no complete cytogenetic response (CCgR)
at 18 months was 11 %. Later the patient was lost during
follow-up.
Results
Prior to the IM-treatment banding cytogenetics re-
vealed a karyotype of 46,XY,t(9;22)(q34.1;q11.2)[20].
After 13 month IM-treatment the karyotype was
46,XY,t(9;22)(q34.1;q11.2)[11]/46,XY[9]. However, after
interrupted involuntarily IM-treatment for 16 months
banding cytogenetics revealed a karyotype of
49,XY,+8,+8,t(9;22)(q34.1;q11.2),+19,inv dup(22)[6]/48,
XY,+8,+8,t(9;22)(q34.1;q11.2),inv dup(22)[1]/48,XY,+8,t
(9;22)(q34.1;q11.2),+19,inv dup(22)[3]/46,XY[10] (Fig. 1).
Further on molecular cytogenetic studies were performed
(Fig. 2). Dual-color-FISH prior and post to IM-treatment
using a specific probe for BCR and ABL1 revealed two fu-
sion signals, on the der(9) and der(22), respectively (data
not shown). Whereas, after interrupted IM-treatment
there were: one BCR/ABL1 fusion signal on a der(9)
one red signal on chromosome 9, and three green
signals, one on chromosome 22 and two on an inv
dup(22) (Fig. 2a). Chromosomes 9 and 22 were stud-
ied with whole chromosome painting (WCP) probes
and did not provide any hint on cryptic translocations
(data not shown). Multicolor banding (MCB) using a
specific probe for chromosome 22 revealed a inver-
sion and duplication of der(22) (Fig. 2b). A probe
specific for alpha satellite regions of chromosomes
14/22 probe confirmed the presence of an inv
dup(22) (Fig. 2c). RT-PCR prior and after the IM-
treatment confirmed the presence of the BCR-ABL1
fusion (b3a2 transcript) revealing a major M-BCR
transcript, most often identified in CML (data not
shown). Thus, the following final karyotype after
interrupted IM-treatment was determined:
Conclusions
According to the literature, BC of CML may be mye-
loid or lymphoid. Approximately 15–20 % of patients
in BC retain the Ph + cell population unaltered,
whereas 80–85 % of the cases undego karyotypic evo-
lution [1]. The most common secondary chromo-
somal aberrations in addition to a Ph-chromosome
are +8, +Ph, i(17q) and +19. Other chromosomal ab-
errations are less frequent, as -Y, +21, +17, −7, and
−17 [1, 6]. Hyperdiploidy is not common in CML
cases [7], however it is a common finding in advanced
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phase-CML patients [6, 8], and it was already reported in
one CML-CP patient as a secondary chromosomal aberra-
tion after IM therapy [9].
The der(22) inv dup(22)(q11.2)t(9.22)(q34;q11.2) is an
uncommon event in CML-advanced phase. However,
this chromosomal aberration was observed in 6 cases be-
fore (the majority were CML-advanced phase), and it
was product of a der(22)t(9;22)(q34;q11.2); the BCR/
ABL1 fusion remained on such inv dup(22) derivatives
[10-13]. In the present case, we noted an inv
dup(22)(q11.23) without presence ABL1 signal on de-
rivative 22. To our knowledge, BC characterized by a
inv dup(22)(q11.23) without presence ABL1 signal on
inv dup(22) associated with tetrasomy 8 and trisomy
19 has not been reported together in CML, yet [14].
Maybe submicroscopic structures of DNA-sequences
in chromosome 22 are herfore responsible [15] How-
ever, tetrasomy 8 is not a rare event in advanced
phase-CML; more than 50 such cases are listed in
Mitelman Database [14].
Fig. 2 Karyotype and chromosomal aberrations were confirm ed using molecular cytogenetic approaches. a FISH using probes for BCR (green)
and ABL (red) showed one red signal on normal chromosome 9; three green signals, one on normal chromosome 22 and two on der(22); BCR/
ABL1 fusion on der(9) with absent of an ABL1 signal on der(22). b The application of MCB (22) characterized the inv dup(22)(q11.23)
comprehensively. c FISH using alpha satellite probe for chromosomes 14 and 22 together revealed two centromers on der(22). Abbreviations: # =
chromosome; der = derivative chromosome
Fig. 1 GTG-banding revealed a 49,XY,+8,+8,t(9;22),+19,inv dup(22). All derivative chromosomes are shown and with arrow
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Clinical resistance by BCR-ABL1 amplification mech-
anism is uncommon, but not a really rare event in CML
resistance to treatment. Amplification of the Ph chromo-
some on conventional karyotyping may present as
double Ph, dicentric Ph, double minutes, or masked Ph
and inverted duplication of Ph [13, 16]. However,
inverted duplication is unique structure and it is related
to a DNA amplification event, which led to increased ex-
pression of bcr-abl protein [17, 18]. Thus, the inv
dup(22) derivative is not easily connected with IM-
resistance.
CML patients in AP and myeloid BC treated with
400 or 600 mg of IM can show major cytogenetic re-
sponse [9, 10, 19]. However, our patient achieved only
a minor cytogenetic response followed 13 months of
IM treatment. Aberrations like inv dup(22)(q11.23)
without presence ABL1 signal on inv dup(22) associ-
ated with tetrasomy 8 and trisomy 19 were noted
after the reported patient stopped IM treatment in-
voluntarily for overall 16 months. Thus, it is unclear,
still unlikely, that such kind of karyotypic changes
might have been seen in this patient in connection
with IM-resistance development. In conclusion the
present case is one of the rare examples, where infor-
tune political circumstances lead to unintentional
interruption of a successful IM-treatment in a Syrian
CML-patient. It is thus a unique example for which
cytogenetic changes may appear during 16 month
interruption of IM-treatment. Trisomy 8 and 19 have
earlier been reported as secondary events in untreated
or treated CML in BC. The inv dup(22)(q11.23) seen




Chromosome analysis applying GTG-banding according
to standard procedures [20] was performed prior IM
treatment. 20 metaphase cells derived from unstimulated
bone marrow culture were analyzed. Karyotypes were
described according to the International System for
Human Cytogenetic Nomenclature (ISCN 2013) [21].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using the LSI
BCR/ABL dual color dual fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA), alpha
satellite probes for chromosomes 14 and 22 (Qbiogene,
MP Biomedicales, Santa Ana, CA, USA) were applied
together with whole chromosome painting (WCP) probe
for chromosomes 9 and 22 (MetaSystems, Altlussheim,
Germany) according to manufacturer's instructions [20].
Also a multicolor banding probe (MCB) sets based on
microdissection derived region-specific libraries for
chromosome 22 was applied as previously described
[22]. A minimum of 10 metaphase spreads was analyzed,
using a fluorescence microscope (AxioImager.Z1 mot,
Carl Zeiss Ltd., Hertfordshir, UK) equipped with appro-
priate filter sets to discriminate between a maximum of
five fluorochromes plus the counterstain DAPI (4',6-
diamino-2-phenylindole). Image capture and processing
were performed using an ISIS imaging system (MetaSys-
tems, Altlussheim, Germany).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
and for BCR/ABL1 fusion transcripts
Total RNA extracted from peripheral blood sample
using the InviTrap RNA kit (Invitek, Berlin, Germany)
according to the manufacturer’s recommendations.
cDNA was prepared from 5 μg of total RNA with the
Genequality BCR-ABL1 kit (AB Analitica, Padova, Italy)
and BCR-ABL1 fusion transcript was performed accord-
ing to the manufacturer’s instructions (AB Analitica,
Padova, Italy).
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Written informed consent was obtained from the patient
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